Financials in USD. Standardized financial statements.
A compact view of how Spectrum Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $10.11M | $0 | $0 | $22.61M | $109.33M | $128.37M | $146.44M | $162.56M | $186.83M | $155.85M |
| Revenue Growth? | 0.0% | 0.0% | -100.0% | -79.3% | -14.8% | -12.3% | -9.9% | -13.0% | +19.9% | 0.0% |
| Cost of Revenue? | $1.79M | $0 | $0 | $12.01M | $26.76M | $47.22M | $35.84M | $27.69M | $27.04M | $28.58M |
| Gross Profit? | $8.32M | $0 | $0 | $10.61M | $82.58M | $81.15M | $110.60M | $134.87M | $159.79M | $127.27M |
| Gross Margin? | +82.3% | 0.0% | 0.0% | +46.9% | +75.5% | +63.2% | +75.5% | +83.0% | +85.5% | +81.7% |
| Operating Expenses? | $81.02M | $147.70M | $169.73M | $140.70M | $213.75M | $177.81M | $172.23M | $175.60M | $191.36M | $166.06M |
| Operating Income? | -$72.70M | -$147.70M | -$169.73M | -$144.03M | -$131.18M | -$96.66M | -$61.63M | -$40.73M | -$31.57M | -$38.78M |
| EBITDA? | -$77.06M | -$147.42M | -$169.47M | -$154.59M | -$93.50M | -$68.62M | -$34.80M | -$3.66M | -$11.65M | -$21.58M |
| Income Before Tax | -$78.06M | -$158.43M | -$171.33M | -$144.59M | -$120.01M | -$108.03M | -$70.83M | -$50.38M | -$43.53M | -$36.64M |
| Income Tax Expense | $46,000 | $4,000 | -$60,000 | -$9.21M | $1,000 | -$16.78M | -$2.31M | $406,000 | $2.19M | $25.50M |
| Net Income? | -$78.10M | -$158.44M | -$171.27M | -$135.39M | -$120.01M | -$91.25M | -$68.51M | -$50.78M | -$45.72M | -$62.13M |
| EPS? | $-0.43 | $-1.02 | $-1.38 | $-1.22 | $-1.16 | $-1.07 | $-0.94 | $-0.78 | $-0.71 | $-1.02 |
| Diluted EPS? | $-0.43 | $-1.02 | $-1.38 | $-1.22 | $-1.16 | $-1.07 | $-0.94 | $-0.78 | $-0.71 | $-1.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality